ABIOMED, Inc. ABMD reported first-quarter fiscal 2020 earnings per share (EPS) of $1, which beat the Zacks Consensus Estimate by a penny. The figure rose 28.2% year over year.
The Zacks Rank #4 (Sell) company’s revenues came in at $207.7 million, missing the Zacks Consensus Estimate of $210.6 million. However, the metric improved 15.4% from the prior-year quarter.
Fiscal Q1 in Detail
Worldwide Impella heart pump revenues in the reported quarter totaled $199.9 million, reflecting an increase of 15% year over year.
U.S. Impella product revenues totaled $168.3 million, an increase of 11% year over year. Per management, U.S. patient usage of the Impella heart pumps rose 13% in the quarter.
Outside the United States, Impella product revenues totaled $31.5 million, highlighting an increase of 44% year over year. Japan revenues were $8.5 million in the quarter, up a substantial 227% year over year.
ABIOMED, Inc. Price, Consensus and EPS Surprise
ABIOMED, Inc. price-consensus-eps-surprise-chart | ABIOMED, Inc. Quote
Margin Trend
In the quarter under review, gross profit totaled $170.6 million, up 14.4% year over year. Gross margin in the quarter was 82.1% of net revenues, down 80 basis points (bps) year over year. Research & Development (R&D) costs grossed $23.8 million, up 11.8% year over year.
Operating income totaled $60.7 million, up 30% on a year-over-year basis. Operating margin was 29.2%, up 320 bps.
Financial Condition
ABIOMED’s balance sheet remains debt free. The company ended the fiscal first quarter with $526.7 million of cash and marketable securities.
Guidance Slashed
For fiscal 2020, ABIOMED expects total revenues in the range of $885-$925 million, an increase of 15% to 20% year over year. This range is below the earlier provided guidance range of $900-$945 million, calling for a year-over-year increase of 17-23%. The Zacks Consensus Estimate for the same stands at $925.3 million, slightly above the projected range.
Summing Up
ABIOMED exited the fiscal first quarter on a mixed note. The company continues to gain from its flagship Impella, which saw a strong quarter. Impella’s patient success stories and increasing global adoptions are added positives. Revenues from Japan skyrocketed in the quarter. Considerable expansion in the operating margin buoys optimism. Meanwhile, surging R&D expenses show increasing focus on innovation. Recent product launches and regulatory approvals buoy optimism. Considerable expansion in operating margin is a positive.
On the flip side, the drop in gross margin is disheartening. A slashed guidance for fiscal 2020 adds to the woes.
Earnings of Other MedTech Majors at a Glance
Some better-ranked stocks, which posted solid results this earnings season, are Stryker Corporation SYK, Baxter International Inc. BAX and Intuitive Surgical, Inc. ISRG.
Stryker delivered second-quarter 2019 adjusted EPS of $1.98, beating the Zacks Consensus Estimate by 2.6%. Its revenues of $3.65 billion surpassed the Zacks Consensus Estimate by 1.4%. The company currently carries a Zacks Rank of 2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Baxter delivered second-quarter 2019 adjusted EPS of 89 cents, which surpassed the Zacks Consensus Estimate of 81 cents by 9.9%. Its revenues of $2.84 billion outpaced the Zacks Consensus Estimate of $2.79 billion by 1.9%. The company currently has a Zacks Rank #2.
Intuitive Surgical reported second-quarter 2019 adjusted EPS of $3.25, which beat the Zacks Consensus Estimate of $2.85. Its revenues of $1.1 billion surpassed the Zacks Consensus Estimate of $1.03 billion. The company sports a Zacks Rank #1 at present.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment